Rachael Fleurence

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. ncbi A systematic review of augmentation strategies for patients with major depressive disorder
    Rachael Fleurence
    Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA
    Psychopharmacol Bull 42:57-90. 2009
  2. ncbi Review of the economic and quality-of-life burden of cervical human papillomavirus disease
    Rachael L Fleurence
    Health Care Analytics Group, United BioSource Corporation, Bethesda, MD, USA
    Am J Obstet Gynecol 196:206-12. 2007
  3. ncbi The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature
    Rachael L Fleurence
    Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Bethesda, Maryland 20814, USA
    Pharmacoeconomics 25:913-33. 2007
  4. ncbi Setting priorities for research: a practical application of 'payback' and expected value of information
    Rachael L Fleurence
    Department of Health Sciences, York Trials Unit, University of York, Heslington York, UK
    Health Econ 16:1345-57. 2007
  5. ncbi Rates and probabilities in economic modelling: transformation, translation and appropriate application
    Rachael L Fleurence
    United BioSource Corporation, Health Care Analytics Group, Bethesda, Maryland 20814, USA
    Pharmacoeconomics 25:3-6. 2007
  6. ncbi Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature
    Rachael Fleurence
    Health Care Analytics Group, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    J Rheumatol 33:2124-31. 2006
  7. ncbi Economics of atypical antipsychotics in bipolar disorder: a review of the literature
    Rachael L Fleurence
    United BioSource Corporation, Health Care Analytics Group, Bethesda, Maryland 20814, USA
    CNS Drugs 20:591-9. 2006
  8. ncbi Cost-effectiveness of pressure-relieving devices for the prevention and treatment of pressure ulcers
    Rachael L Fleurence
    The MEDTAP Institute, UBC, USA
    Int J Technol Assess Health Care 21:334-41. 2005
  9. ncbi Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
    Rachael L Fleurence
    The MEDTAP Institute at UBC, Bethesda, MD 20814, USA
    Osteoporos Int 17:29-40. 2006
  10. doi The critical role of observational evidence in comparative effectiveness research
    Rachael L Fleurence
    Evidence Review and Synthesis Practice, United BioSource Corporation, Bethesda, Maryland, USA
    Health Aff (Millwood) 29:1826-33. 2010

Detail Information

Publications16

  1. ncbi A systematic review of augmentation strategies for patients with major depressive disorder
    Rachael Fleurence
    Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA
    Psychopharmacol Bull 42:57-90. 2009
    ....
  2. ncbi Review of the economic and quality-of-life burden of cervical human papillomavirus disease
    Rachael L Fleurence
    Health Care Analytics Group, United BioSource Corporation, Bethesda, MD, USA
    Am J Obstet Gynecol 196:206-12. 2007
    ..The purpose of this study was to conduct a systematic literature review on the economic burden and health-related quality-of-life impact of cervical human papillomavirus disease...
  3. ncbi The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature
    Rachael L Fleurence
    Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Bethesda, Maryland 20814, USA
    Pharmacoeconomics 25:913-33. 2007
    ..Screening strategies for low BMD followed by bisphosphonate treatment should also be considered in the general female population aged >65 years in the UK and US and in patients with rheumatoid arthritis initiating corticosteroid therapy...
  4. ncbi Setting priorities for research: a practical application of 'payback' and expected value of information
    Rachael L Fleurence
    Department of Health Sciences, York Trials Unit, University of York, Heslington York, UK
    Health Econ 16:1345-57. 2007
    ..Setting priorities for research using economic in addition to scientific criteria can ensure that resources are spent efficiently and equitably...
  5. ncbi Rates and probabilities in economic modelling: transformation, translation and appropriate application
    Rachael L Fleurence
    United BioSource Corporation, Health Care Analytics Group, Bethesda, Maryland 20814, USA
    Pharmacoeconomics 25:3-6. 2007
    ..How the transformed rates and probabilities may be used in economic models is then described and some recommendations are suggested...
  6. ncbi Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature
    Rachael Fleurence
    Health Care Analytics Group, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    J Rheumatol 33:2124-31. 2006
    ..Four new biologic treatments have been approved for several autoimmune disorders. Economic evaluations have been used to model their cost-effectiveness...
  7. ncbi Economics of atypical antipsychotics in bipolar disorder: a review of the literature
    Rachael L Fleurence
    United BioSource Corporation, Health Care Analytics Group, Bethesda, Maryland 20814, USA
    CNS Drugs 20:591-9. 2006
    ..A better understanding of the complex interplay between effectiveness, safety, quality of life, adherence and resource use should ultimately contribute to improving the treatment of bipolar disorder...
  8. ncbi Cost-effectiveness of pressure-relieving devices for the prevention and treatment of pressure ulcers
    Rachael L Fleurence
    The MEDTAP Institute, UBC, USA
    Int J Technol Assess Health Care 21:334-41. 2005
    ....
  9. ncbi Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
    Rachael L Fleurence
    The MEDTAP Institute at UBC, Bethesda, MD 20814, USA
    Osteoporos Int 17:29-40. 2006
    ..Such changes are reflected in the studies that were reviewed. The development of economic models should be an iterative process that incorporates new information, whether clinical or methodological, as it becomes available...
  10. doi The critical role of observational evidence in comparative effectiveness research
    Rachael L Fleurence
    Evidence Review and Synthesis Practice, United BioSource Corporation, Bethesda, Maryland, USA
    Health Aff (Millwood) 29:1826-33. 2010
    ..But some decisions based on observational studies have turned out to be wrong. We recommend that researchers adopt a "body of evidence" approach that includes both randomized and observational evidence...
  11. doi Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis
    Rachael L Fleurence
    United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA
    Pharmacoeconomics 28:295-306. 2010
    ..Further research should explore this finding...
  12. doi Economic burden of multiple sclerosis: a systematic review of the literature
    Huseyin Naci
    Center for Health Economics and Science Policy, United BioSource Corporation, London, UK
    Pharmacoeconomics 28:363-79. 2010
    ....
  13. ncbi Cost-effectiveness of fracture prevention treatments in the elderly
    Rachael L Fleurence
    Department of Health Sciences, University of York, Heslington, UK
    Int J Technol Assess Health Care 20:184-91. 2004
    ..The cost-effectiveness of fracture prevention treatments (vitamin D and calcium and hip protectors) in male and female populations older than seventy years of age in the United-Kingdom was investigated...
  14. ncbi Setting priorities for research
    Rachael L Fleurence
    Department of Health Sciences, Seebohm Rowntree Building, Area 4, University of York, York YO10 5DQ, UK
    Health Policy 69:1-10. 2004
    ..However, this method still requires further work to evaluate how research outcomes can then be communicated to clinical practitioners and how practitioners can be encouraged to implement them...
  15. doi Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective
    Feng Pan
    United BioSource Corporation, Bethesda, Maryland, USA
    Clin Ther 32:2444-56. 2010
    ..The US Food and Drug Administration has approved a 5-day outpatient decitabine dosing regimen, which might reduce administration costs compared with the standard 3-day inpatient regimen...
  16. doi The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature
    Huseyin Naci
    Center for Health Economics and Science Policy, United BioSource Corporation, 20 Bloomsbury Square, London, UK
    J Med Econ 13:78-89. 2010
    ..Multiple sclerosis (MS) is a debilitating disease, accompanied by neurological symptoms of varying severity. Utilities are a key summary index measure used in assessing health-related quality of life in individuals with MS...